Targeted drug delivery to lymphocytes: A route to site-specific immunomodulation?

Molecular Pharmaceutics

Volumn 7, Issue 6, 2010, Pages 2297-2309

  Trevaskis, Natalie L ^a   Charman, William N ^a   Porter, Christopher J H ^a  

^a MONASH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

2 METHYL 3 (1 NAPHTHOYL) 1 PROPYLINDOLE; CD4 ANTIGEN; CD8 ANTIGEN; CHLORPHENOTANE; CYCLOSPORIN; DIAZEPAM; HALOFANTRINE; INTERLEUKIN 10; INTERLEUKIN 4; MITOGENIC AGENT; OLEIC ACID; RAPAMYCIN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANIMAL CELL; ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; AUTOIMMUNE DISEASE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG EXPOSURE; DRUG FORMULATION; DRUG POTENCY; DRUG SELECTIVITY; DRUG TARGETING; DRUG TRANSPORT; EX VIVO STUDY; GASTROINTESTINAL TRACT; GRAFT REJECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOMODULATION; INTESTINE LYMPH; LIPOPHILICITY; LYMPHOCYTE; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT;

ANIMALS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTOKINES; DDT; DRUG DELIVERY SYSTEMS; FLOW CYTOMETRY; IMMUNOMODULATION; INDOLES; LYMPHOCYTES; MALE; MITOGENS; PHENANTHRENES; RATS; RATS, SPRAGUE-DAWLEY; SIROLIMUS;

EID: 78649964349     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp100259a     Document Type: Article

References (63)

1. Kelleher, A. D.; Zaunders, J. J. Decimated or missing in action: CD4+ T cells as targets and effectors in the pathogenesis of primary HIV infection Curr. HIV/AIDS Rep. 2006, 3 (1) 5-12
2. Picker, L. J. Immunopathogenesis of acute AIDS virus infection Curr. Opin. Immunol. 2006, 18 (4) 399-405
3. Dumont, F. J. Treatment of transplant rejection: are the traditional immunosuppressants good enough Curr. Opin. Invest. Drugs 2001, 2 (3) 357-63
4. Roca, B. Adverse drug reactions to antiretroviral medication Front. Biosci. 2009, 14, 1785-92
5. Reddy, S. T.; van der Vlies, A. J.; Simeoni, E.; Angeli, V.; Randolph, G. J.; O'Neil, C. P.; Lee, L. K.; Swartz, M. A.; Hubbell, J. A. Exploiting lymphatic transport and complement activation in nanoparticle vaccines Nat. Biotechnol. 2007, 25 (10) 1159-64
6. Hubbell, J. A.; Thomas, S. N.; Swartz, M. A. Materials engineering for immunomodulation Nature 2009, 462 (7272) 449-60
7. Fahmy, T. M.; Fong, P. M.; Park, J.; Constable, T.; Saltzman, W. M. Nanosystems for simultaneous imaging and drug delivery to T cells AAPS J. 2007, 9 (2 E171-80
8. Dinauer, N.; Balthasar, S.; Weber, C.; Kreuter, J.; Langer, K.; von Briesen, H. Selective targeting of antibody-conjugated nanoparticles to leukemic cells and primary T-lymphocytes Biomaterials 2005, 26 (29) 5898-906
9. Ehrhardt, C.; Kneuer, C.; Bakowsky, U. Selectins-an emerging target for drug delivery Adv. Drug Delivery Rev. 2004, 56 (4) 527-49
10. Yusuf-Makagiansar, H.; Siahaan, T. J. Binding and internalization of an LFA-1-derived cyclic peptide by ICAM receptors on activated lymphocyte: a potential ligand for drug targeting to ICAM-1-expressing cells Pharm. Res. 2001, 18 (3) 329-35
11. Theofilopoulous, A. N.; Constantin, A. B. The molecular pathology of autoimmune diseases, 2nd ed.; Taylor and Francis: Ann Arbor, 2002.
12. Cesta, M. F. Normal structure, function, and histology of mucosa-associated lymphoid tissue Toxicol. Pathol. 2006, 34 (5) 599-608
13. Guy-Grand, D.; Vassalli, P. Gut intraepithelial T lymphocytes Curr. Opin. Immunol. 1993, 5 (2) 247-52
14. Porter, C. J. H.; Trevaskis, N. L.; Charman, W. N. Lipids and lipid-based formulations: optimizing the oral delivery of lipophilic drugs Nat. Rev. Drug Discovery 2007, 6 (3) 231-48
15. Lipinski, C. A.; Lombardo, F.; Dominy, B. W.; Feeney, P. J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings Adv. Drug Delivery Rev. 2001, 46 (1-3) 3-26 (Pubitemid 33653411)
16. Charman, W. N.; Stella, V. J. Estimating the maximum potential for intestinal lymphatic transport of lipophilic drug molecules Int. J. Pharm. 1986, 34, 175-8
17. Gershkovich, P.; Fanous, J.; Qadri, B.; Yacovan, A.; Amselem, S.; Hoffman, A. The role of molecular physicochemical properties and apolipoproteins in association of drugs with triglyceride-rich lipoproteins: in-silico prediction of uptake by chylomicrons J. Pharm. Pharmacol. 2009, 61 (1) 31-9
18. Caliph, S. M.; Charman, W. N.; Porter, C. J. H. Effect of short-, medium-, and long-chain fatty acid-based vehicles on the absolute oral bioavailability and intestinal lymphatic transport of halofantrine and assessment of mass balance in lymph-cannulated and non-cannulated rats J. Pharm. Sci. 2000, 89 (8) 1073-84
19. Holm, R.; Mullertz, A.; Christensen, E.; Hoy, C. E.; Kristensen, H. G. Comparison of total oral bioavailability and the lymphatic transport of halofantrine from three different unsaturated triglycerides in lymph-cannulated conscious rats Eur. J. Pharm. Sci. 2001, 14 (4) 331-7
20. Khoo, S. M.; Edwards, G. A.; Porter, C. J. H.; Charman, W. N. A conscious dog model for assessing the absorption, enterocyte-based metabolism, and intestinal lymphatic transport of halofantrine J. Pharm. Sci. 2001, 90 (10) 1599-607
21. Porter, C. J. H.; Charman, S. A.; Humberstone, A. J.; Charman, W. N. Lymphatic transport of halofantrine in the conscious rat when administered as either the free base or the hydrochloride salt: effect of lipid class and lipid vehicle dispersion J. Pharm. Sci. 1996, 85 (4) 357-61
22. Porter, C. J. H.; Charman, S. A.; Charman, W. N. Lymphatic transport of halofantrine in the triple-cannulated anesthetized rat model: effect of lipid vehicle dispersion J. Pharm. Sci. 1996, 85 (4) 351-6
23. Kaukonen, A. M.; Boyd, B. J.; Porter, C. J. H.; Charman, W. N. Drug solubilization behavior during in vitro digestion of simple triglyceride lipid solution formulations Pharm. Res. 2004, 21 (2) 245-53
24. Gershkovich, P.; Hoffman, A. Uptake of lipophilic drugs by plasma derived isolated chylomicrons: linear correlation with intestinal lymphatic bioavailability Eur. J. Pharm. Sci. 2005, 26 (5) 394-404
25. Sieber, S. M.; Cohn, V. H.; Wynn, W. T. The entry of foreign compounds into the thoracic duct lymph of the rat Xenobiotica 1974, 4 (5) 265-84
26. Forrest, M. L.; Won, C. Y.; Malick, A. W.; Kwon, G. S. In vitro release of the mTOR inhibitor rapamycin from poly(ethylene glycol)-b-poly(epsilon- caprolactone) micelles J. Controlled Release 2006, 110 (2) 370-7
27. Simamora, P.; Alvarez, J. M.; Yalkowsky, S. H. Solubilization of rapamycin Int. J. Pharm. 2001, 213 (1-2) 25-9
28. Takada, K.; Shibata, N.; Yoshimura, H.; Masuda, Y.; Yoshikawa, H.; Muranishi, S.; Oka, T. Promotion of the selective lymphatic delivery of cyclosporin A by lipid-surfactant mixed micelles J. Pharmacobio-Dyn. 1985, 8 (4) 320-3
29. Ueda, C. T.; Lemaire, M.; Gsell, G.; Nussbaumer, K. Intestinal lymphatic absorption of cyclosporin A following oral administration in an olive oil solution in rats Biopharm. Drug Dispos. 1983, 4 (2) 113-24
30. Katayama, N.; Tanaka, R.; Ohno, Y.; Ueda, C. T.; Houjou, T.; Takada, K. Implantable slow release cyclosporin A (CYA) delivery system to thoracic lymph duct Int. J. Pharm. 1995, 115 (1) 87-93
31. Takada, K.; Yoshimura, H.; Yoshikawa, H.; Muranishi, S.; Yasumura, T.; Oka, T. Enhanced Selective Lymphatic Delivery of Cyclosporin A by Solubilizers and Intensified Immunosuppressive Activity Against Mice Skin Allograft Pharm. Res. 1986, 3 (1) 48-51
32. Trevaskis, N. L.; Porter, C. J. H.; Charman, W. N. Bile increases intestinal lymphatic drug transport in the fasted rat Pharm. Res. 2005, 22 (11) 1863-70
33. Johnson, B. M.; Chen, W.; Borchardt, R. T.; Charman, W. N.; Porter, C. J. H. A kinetic evaluation of the absorption, efflux, and metabolism of verapamil in the autoperfused rat jejunum J. Pharmacol. Exp. Ther. 2003, 305 (1) 151-8
34. Trevaskis, N. L.; Porter, C. J. H.; Charman, W. N. The lymph lipid precursor pool is a key determinant of intestinal lymphatic drug transport J. Pharmacol. Exp. Ther. 2006, 316 (2) 881-91
35. Miura, S.; Imaeda, H.; Shiozaki, H.; Ohkubo, N.; Tashiro, H.; Serizawa, H.; Tsuchiya, M.; Tso, P. Increased proliferative response of lymphocytes from intestinal lymph during long chain fatty acid absorption Immunology 1993, 78 (1) 142-6
36. Diaz-Romero, J.; Vogt, G.; Weckbecker, G. A small-volume technique for simultaneous immunophenotyping and apoptosis detection in rat whole blood by four-color flow cytometry Cytometry 2002, 47 (4) 265-75
37. Bocci, G.; Danesi, R.; Di Paolo, A. D.; Innocenti, F.; Allegrini, G.; Falcone, A.; Melosi, A.; Battistoni, M.; Barsanti, G.; Conte, P. F.; Del Tacca, M. Comparative pharmacokinetic analysis of 5-fluorouracil and its major metabolite 5-fluoro-5,6-dihydrouracil after conventional and reduced test dose in cancer patients Clin. Cancer Res. 2000, 6 (8) 3032-7
38. Trevaskis, N. L.; McEvoy, C. L.; McIntosh, M. P.; Edwards, G. A.; Shanker, R. M.; Charman, W. N.; Porter, C. J. H. The role of the intestinal lymphatics in the absorption of two highly lipophilic cholesterol ester transfer protein inhibitors (CP524,515 and CP532,623) Pharm. Res. 2010, 27 (5) 878-93
39. Trevaskis, N. L.; Porter, C. J. H.; Charman, W. N. An examination of the interplay between enterocyte-based metabolism and lymphatic drug transport in the rat Drug Metab. Dispos. 2006, 34 (5) 729-33
40. Shapiro, H. M. Practical Flow Cytometry, 4th ed.; John Wiley and Sons: Hoboken, NJ, 2003.
41. Ullrich, O.; Merker, K.; Timm, J.; Tauber, S. Immune control by endocannabinoids-new mechanisms of neuroprotection J. Neuroimmunol. 2007, 184 (1-2) 127-35
42. Montecucco, F.; Burger, F.; Mach, F.; Steffens, S. CB2 cannabinoid receptor agonist JWH-015 modulates human monocyte migration through defined intracellular signaling pathways Am. J. Physiol. 2008, 294 (3) H1145-55
43. Lombard, C.; Nagarkatti, M.; Nagarkatti, P. CB2 cannabinoid receptor agonist, JWH-015, triggers apoptosis in immune cells: potential role for CB2-selective ligands as immunosuppressive agents Clin. Immunol. 2007, 122 (3) 259-70
44. Arevalo-Martin, A.; Vela, J. M.; Molina-Holgado, E.; Borrell, J.; Guaza, C. Therapeutic action of cannabinoids in a murine model of multiple sclerosis J. Neurosci. 2003, 23 (7) 2511-6
45. Klegeris, A.; Bissonnette, C. J.; McGeer, P. L. Reduction of human monocytic cell neurotoxicity and cytokine secretion by ligands of the cannabinoid-type CB2 receptor Br. J. Pharmacol. 2003, 139 (4) 775-86
46. Dandekar, S. Pathogenesis of HIV in the gastrointestinal tract Curr. HIV/AIDS Rep. 2007, 4 (1) 10-5
47. Umeda, M.; Marusawa, H.; Seno, H.; Katsurada, A.; Nabeshima, M.; Egawa, H.; Uemoto, S.; Inomata, Y.; Tanaka, K.; Chiba, T. Hepatitis B virus infection in lymphatic tissues in inactive hepatitis B carriers J. Hepatol. 2005, 42 (6) 806-12
48. Kessel, A.; Toubi, E. Chronic HCV-related autoimmunity: A consequence of viral persistence and lymphotropism Curr. Med. Chem. 2007, 14 (5) 547-54
49. Spiegel, M.; Schneider, K.; Weber, F.; Weidmann, M.; Hufert, F. T. Interaction of severe acute respiratory syndrome-associated coronavirus with dendritic cells J. Gen. Virol. 2006, 87, 1953-60
50. von Messling, V.; Svitek, N.; Cattaneo, R. Receptor (SLAM [CD150]) recognition and the V protein sustain swift lymphocyte-based invasion of mucosal tissue and lymphatic organs by a morbillivirus J. Virol. 2006, 80 (12) 6084-92
51. Sheer, T. A.; Coyle, W. J. Gastrointestinal tuberculosis Curr. Gastroenterol. Rep. 2003, 5 (4) 273-8
52. Trevaskis, N. L.; Charman, W. N.; Porter, C. J. H. Lipid-based delivery systems and intestinal lymphatic drug transport: a mechanistic update Adv. Drug Delivery Rev. 2008, 60 (6) 702-16
53. Trevaskis, N. L.; Shanker, R. M.; Charman, W. N.; Porter, C. J. H. The Mechanism of Lymphatic Access of Two Cholesteryl Ester Transfer Protein Inhibitors (CP524,515 and CP532,623) and Evaluation of Their Impact on Lymph Lipoprotein Profiles Pharm. Res. 2010, 27 (9) 1949-64
54. Miura, S.; Sekizuka, E.; Nagata, H.; Oshio, C.; Minamitani, H.; Suematsu, M.; Suzuki, M.; Hamada, Y.; Kobayashi, K.; Asakura, H. Increased lymphocyte transport by lipid absorption in rat mesenteric lymphatics Am. J. Physiol. 1987, 253 (5 Part 1) G596-600
55. Tsuzuki, Y.; Miura, S.; Kurose, I.; Suematsu, M.; Higuchi, H.; Shigematsu, T.; Kimura, H.; Serizawa, H.; Hokari, R.; Akiba, Y.; Yagita, H.; Okumura, K.; Tso, P.; Granger, D. N.; Ishii, H. Enhanced lymphocyte interaction in postcapillary venules of Peyer's patches during fat absorption in rats Gastroenterology 1997, 112 (3) 813-25
56. Manhart, N.; Vierlinger, K.; Akomeah, R.; Bergmeister, H.; Spittler, A.; Roth, E. Influence of enteral diets supplemented with key nutrients on lymphocyte subpopulations in Peyer's patches of endotoxin-boostered mice Clin. Nutr. 2000, 19 (4) 265-9
57. Salmi, M.; Jalkanen, S. Lymphocyte homing to the gut: attraction, adhesion, and commitment Immunol. Rev. 2005, 206, 100-13
58. Calder, P. C.; Yaqoob, P.; Newsholme, E. A. Triacylglycerol metabolism by lymphocytes and the effect of triacylglycerols on lymphocyte proliferation Biochem. J. 1994, 298 (Part 3) 605-11
59. Cuthbert, J. A.; Lipsky, P. E. Promotion of human T lymphocyte activation and proliferation by fatty acids in low density and high density lipoproteins J. Biol. Chem. 1986, 261 (8) 3620-7
60. Jurgens, G.; Xu, Q. B.; Huber, L. A.; Bock, G.; Howanietz, H.; Wick, G.; Traill, K. N. Promotion of lymphocyte growth by high density lipoproteins (HDL). Physiological significance of the HDL binding site J. Biol. Chem. 1989, 264 (15) 8549-56
61. Cuthbert, J. A.; Lipsky, P. E. Lipoproteins may provide fatty acids necessary for human lymphocyte proliferation by both low density lipoprotein receptor-dependent and -independent mechanisms J. Biol. Chem. 1989, 264 (23) 13468-74
62. Busbee, D. L.; Rankin, P. W.; Payne, D. M.; Jasheway, D. W. Binding of benzo[a]pyrene and intracellular transport of a bound electrophilic benzo[a]pyrene metabolite by lipoproteins Carcinogenesis 1982, 3 (10) 1107-12
63. Kaminski, N. E.; Wells, D. S.; Dauterman, W. C.; Roberts, J. F.; Guthrie, F. E. Macrophage uptake of a lipoprotein-sequestered toxicant: a potential route of immunotoxicity Toxicol. Appl. Pharmacol. 1986, 82 (3) 474-80